IDEXX Laboratories: A Pawsitively Strong Finish to 2021

By Your Finance Correspondent

In a world where every quarter's earnings report feels like a theatrical performance, IDEXX Laboratories, Inc. (NASDAQ: IDXX) just took a bow with its fourth quarter and full year results that are nothing short of a standing ovation. The company reported an impressive EPS of $1.89 for Q4 2021, marking a 12% increase on a comparable basis, despite a 6% dip in reported earnings, thanks to last year?s one-time tax reform windfall in Switzerland. But let?s not dwell on the past; the EPS consensus was met and even exceeded in the hearts of its investors.

A Revenue Forecast to Bark About

IDEXX?s revenue for the fourth quarter hit $801 million, reflecting an 11% growth over the prior year. This growth was driven primarily by a robust 13% increase in CAG Diagnostics recurring revenues. The company?s guidance for 2022 projects a revenue forecast of $3.5 billion to $3.565 billion?a growth rate of 9% to 11%. It seems that IDEXX is well-positioned to continue its tail-wagging ways into the new year.

Growth Trends: CAG Diagnostics Leads the Pack

The Companion Animal Group (CAG) is the star of the show, generating a commendable 14% revenue growth on a reported basis and 13% organically. The demand for clinical services continues to swell, with veterinary practices reporting a 2% growth in same-store clinical visits in Q4 2021. This trend is notable, especially considering the usual seasonal downturns in the industry. As Jay Mazelsky, IDEXX's CEO, stated, "Our highly differentiated diagnostic testing solutions have allowed veterinarians to improve patient care while optimizing their practices."

Looking Ahead: Will the Momentum Continue?

With a projected EPS range of $9.27 to $9.59 for 2022, IDEXX is aiming for an increase of 8% to 11% on a reported basis. The earnings surprise might be in store if the company successfully navigates potential headwinds, including the lingering effects of the COVID-19 pandemic and rising international tax rates that could impact margins.

The company?s commitment to expanding its premium instrument installed base and the continued growth of its cloud-based software capabilities suggest that IDEXX is not just riding the wave of current trends, but actively shaping its future.

Sector Peers: How Does IDEXX Stack Up?

In the broader context, IDEXX's performance reflects a strong recovery within the veterinary diagnostics sector. As clinics adapt to the ongoing demand for clinical services, competitors must also enhance their offerings to keep pace. With IDEXX's strong results, other players in the veterinary space may find themselves barking up the wrong tree if they fail to innovate and capture market share.